Severe atovaquone-resistant Plasmodium falciparum malaria in a Canadian traveller returned from the Indian subcontinent

BACKGROUND We report the first case of atovaquone/proguanil treatment failure in severe Plasmodium falciparum malaria acquired by a non-immune traveller to the Indian subcontinent. Recrudescent infection was complicated by neurological involvement 14 days after directly observed therapy with atovaquone/proguanil. Sequence analysis of the plasmodial cytochrome b gene confirmed a contribution of atovaquone resistance to treatment failure. The recrudescent isolate had a single mutation at position 268 (Tyr268Cys). Video recordings illustrate dramatic but ephemeral manifestations of malaria with neurological involvement.

[1]  S. Brophy,et al.  Interventions for latent autoimmune diabetes (LADA) in adults. , 2011, The Cochrane database of systematic reviews.

[2]  Gregory W. Rose,et al.  Atovaquone-proguanil resistance in imported falciparum malaria in a young child. , 2008, The Pediatric infectious disease journal.

[3]  B. Neville,et al.  Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. , 2007, JAMA.

[4]  Samir N. Patel,et al.  Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand. , 2007, The American journal of tropical medicine and hygiene.

[5]  K. Kain,et al.  Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). , 2007, The American journal of tropical medicine and hygiene.

[6]  D. Osrin,et al.  Chemoprophylaxis use and the risk of malaria in travelers to Nepal. , 2006, Journal of travel medicine.

[7]  Arjen Dondorp,et al.  Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial , 2005, The Lancet.

[8]  S. Kuhn,et al.  Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. , 2005, The American journal of tropical medicine and hygiene.

[9]  M. Lewis,et al.  Typhoid fever: a massive, single-point source, multidrug-resistant outbreak in Nepal. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  K. Marsh,et al.  Clinical features and pathogenesis of severe malaria. , 2004, Trends in parasitology.

[11]  K. Kain,et al.  Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  R. López-Vélez,et al.  Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Samir N. Patel,et al.  A Molecular Surveillance System for Global Patterns of Drug Resistance in Imported Malaria , 2003, Emerging infectious diseases.

[14]  K. Kain,et al.  Malaria deaths in visitors to Canada and in Canadian travellers: a case series. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[15]  Q. Cheng,et al.  Mutations in Plasmodium falciparumCytochrome b That Are Associated with Atovaquone Resistance Are Located at a Putative Drug-Binding Site , 2000, Antimicrobial Agents and Chemotherapy.

[16]  M. Meremikwu,et al.  Blood transfusion for treating malarial anaemia. , 1999, The Cochrane database of systematic reviews.

[17]  K. Kain,et al.  Imported malaria: prospective analysis of problems in diagnosis and management. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  A. Vaidya,et al.  Atovaquone, a Broad Spectrum Antiparasitic Drug, Collapses Mitochondrial Membrane Potential in a Malarial Parasite* , 1997, The Journal of Biological Chemistry.

[19]  D. Gubler,et al.  Dengue and dengue hemorrhagic fever. , 2014 .

[20]  H. Webster,et al.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. , 1996, The American journal of tropical medicine and hygiene.

[21]  Canadian recommendations for the prevention and treatment of malaria among international travellers. , 1991, Canada diseases weekly report = Rapport hebdomadaire des maladies au Canada.